The protective effects of Ninjin’yoeito against liver steatosis/fibrosis in a non-alcoholic steatohepatitis model mouse

被引：0
|
作者：
Kyohei Takano
Marisa Kaneda
Yayoi Aoki
Nina Fujita
Shigeki Chiba
Seiwa Michihara
Li-Kun Han
Ryuji Takahashi
机构：
[1] Kracie,Kampo Research Laboratory, Pharmaceutical Company
[2] Ltd.,undefined
来源：
Journal of Natural Medicines | 2024年 / 78卷
关键词：
Ninjin’yoeito; Steatosis; Fibrosis; Non-alcoholic steatohepatitis; Choline-deficient L-amino acid-defined high-fat diet;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：514 / 524
页数：10
相关论文
共 50 条
  • [21] Perturbed liver gene zonation in a mouse model of non-alcoholic steatohepatitis
    Zhou, Ye
    Zhao, Yuanqi
    Carbonaro, Marisa
    Chen, Helen
    Germino, Mary
    Adler, Christina
    Ni, Min
    Zhu, Yuan O.
    Kim, Sun Y.
    Altarejos, Judith
    Li, Zhe
    Burczynski, Michael E.
    Glass, David J.
    Sleeman, Mark W.
    Lee, Ann-Hwee
    Halasz, Gabor
    Cheng, Xiping
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2024, 154
  • [22] Predictors of non-alcoholic steatohepatitis and fibrosis in non-alcoholic fatty liver disease.
    Pong, JP
    Elariny, H
    Younoszai, A
    HEPATOLOGY, 2002, 36 (04) : 407A - 407A
  • [23] TAUROURSODEOXYCHOLIC ACID ATTENUATES HEPATIC FIBROSIS IN A MOUSE MODEL OF NON-ALCOHOLIC STEATOHEPATITIS
    Cho, E. J.
    Yu, S. J.
    Lee, J. -H.
    Yoon, J. -H.
    Lee, H. -S.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S485 - S485
  • [24] PANCREATIC STEATOSIS IS NOT ASSOCIATED WITH ADVANCED STAGES OF LIVER FIBROSIS OR GRADE OF STEATOHEPATITIS IN NON-ALCOHOLIC FATTY LIVER DISEASE
    Heymann, Gabriel
    Rahman, Saumik Z.
    Israel, Gary
    Muniraj, Thiruvengadam
    GASTROENTEROLOGY, 2022, 162 (07) : S574 - S575
  • [25] Hepatoprotective effect of tamoxifen on steatosis and non-alcoholic steatohepatitis in mouse models
    Miyashita, Taishi
    Toyoda, Yasuyuki
    Tsuneyama, Koichi
    Fukami, Tatsuki
    Nakajima, Miki
    Yokoi, Tsuyoshi
    JOURNAL OF TOXICOLOGICAL SCIENCES, 2012, 37 (05): : 931 - 942
  • [26] Effect of Losartan on liver fibrosis development in a rat model of non-alcoholic steatohepatitis
    Ibanez, P
    Pizarro, M
    Solis, N
    Aguayo, G
    Duarte, I
    Accatino, L
    Arrese, MA
    GASTROENTEROLOGY, 2004, 126 (04) : A688 - A689
  • [27] Lansoprazole prevents the progression of liver fibrosis in non-alcoholic steatohepatitis model rats
    Nishi, Toshio
    Yamamoto, Yuta
    Yamagishi, Naoko
    Iguchi, Mikitaka
    Tamai, Hideyuki
    Ito, Takao
    Tsuruo, Yoshihiro
    Ichinose, Masao
    Kitano, Masayuki
    Ueyama, Takashi
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2018, 70 (03) : 383 - 392
  • [28] Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model
    Stefano, J. T.
    Pereira, I. V. A.
    Torres, M. M.
    Bida, P. M.
    Coelho, A. M. M.
    Xerfan, M. P.
    Cogliati, B.
    Barbeiro, D. F.
    Mazo, D. F. C.
    Kubrusly, M. S.
    D'Albuquerque, L. A. C.
    Souza, H. P.
    Carrilho, F. J.
    Oliveira, C. P.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2015, 48 (05) : 408 - 414
  • [29] Machine learning to predict progression of non-alcoholic fatty liver to non-alcoholic steatohepatitis or fibrosis
    Ghandian, Sina
    Thapa, Rahul
    Garikipati, Anurag
    Barnes, Gina
    Green-Saxena, Abigail
    Calvert, Jacob
    Mao, Qingqing
    Das, Ritankar
    JGH OPEN, 2022, 6 (03): : 196 - 204
  • [30] NON-ALCOHOLIC STEATOSIS OF THE LIVER
    BOUSTIERE, C
    GAUTHIER, A
    PRESSE MEDICALE, 1985, 14 (20): : 1147 - 1150
12345